Protective Effect of Early High Dose stATins On Cardiovascular and Renal Events in Acute Coronary Syndrome (PRATO-ACS)

Centro Cardiopatici Toscani

Status

Enrolling

Conditions

Acute Coronary Syndrome

Study type

Observational

Funder types

Other

Identifiers

NCT04087200

OSS 15.161

Details and patient eligibility

About

Registration of all ACS patients (STEMI and NSTEMI) admitted to the cardiology ward and scheduled for early invasive strategy. The aim is to evaluate the protective effects of early (on admission) high-dose high-potency statin therapy on early and mid-term cardiac and renal events in this subset of patients.

Full description

Statin-naive patients and those on statin therapy with ACS who are admitted to the cardiology ward of our public (National Health Service) hospital and are scheduled for early invasive strategy receive immediately on admission, always before angiographic procedure, high-dose statin therapy. Either atorvastatin 80 mg or rosuvastatin 40 mg is administered at the discretion of the physician. During hospitalization various pertinent cardiac and renal parameters, including hematological, angiographic, clinical data are registered in a dedicated database. Clinical follow-up and hematological analysis are done 1 month after discharge. A second follow-up, either clinical or by telephone, is done 1 year after discharge.

Enrollment

2,500 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria